A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Phase of Trial: Phase III
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Casimersen (Primary) ; Golodirsenum (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- Acronyms ESSENCE
- Sponsors Sarepta Therapeutics
- 28 Sep 2016 According to a Sarepta Therapeutics media release, the first patient dosed in September 2016.
- 01 Aug 2016 Status changed from not yet recruiting to recruiting.
- 16 Jun 2016 Planned End Date changed from 1 May 2018 to 1 Jun 2021.